His research is focused on the preclinical assessment of antiviral and other therapeutic strategies in the woodchuck animal model for the management of chronic hepatitis B virus (HBV) infection. He is further interested in studying innate and adaptive immunity against HBV and associated liver disease sequelae, including primary liver cancer. The overall goal is to identify viral and host targets for the development of new or improved strategies for the treatment of chronic HBV infection and hepatocellular carcinoma (HCC) by determining the role of immune responses leading to suppression of viral replication, delay of chronic liver disease progression, and prevention of HCC development.